Tributyrin is a natural fat that releases butyrate, a compound gut bacteria make from fiber. Human evidence confirms only that it briefly raises butyrate in the body. Hoped-for benefits for the gut lining, inflammation, blood sugar, liver, and brain rest mostly on cell and animal studies. Safety at supplement doses looks reassuring. (Full Review)

Protocol

Standard Dose

~500 mg 2–3× daily

About 1,000–1,500 mg/day total; start low and titrate over 1–2 weeks.

Timing

Take with food

Dosing with a meal blunts GI discomfort and provides the lipase activity that releases butyrate.

Split Dosing

2–3 doses/day

Dividing the total reduces peak GI load and sustains butyrate exposure given its short duration of action.

Time to effect

Raised Butyrate

Within hours

Target engagement (raised butyrate) is immediate within hours of a dose.

Gut / Systemic Outcomes

Weeks

Any meaningful gut or systemic outcomes, where they occur, would likely require weeks. No well-defined human timeline exists.

Study Intervention Periods

~4 weeks or longer

The small human microbiome study used 21 days; trials use roughly 4-week or longer intervention periods.

Benefits

Medium: Increased systemic butyrate availability

Low: Gut barrier support and intestinal health; anti-inflammatory effects; metabolic and insulin-sensitivity improvements; liver protection

Speculative: Gut–brain and neurocognitive effects; cardiovascular and vascular protection; anticancer / cell-differentiation effects; skeletal muscle and exercise-related effects

Contraindications

Pregnancy or breastfeeding (no safety data)

Severe pancreatic insufficiency

Known intolerance

Pharmaceutical HDAC-inhibitor therapy (medical supervision only)

Advanced organ dysfunction (decompensated liver disease, advanced chronic kidney disease)

Key Interactions

Orlistat (lipase-blocking weight-loss drug)

Other butyrate sources (sodium/calcium-magnesium butyrate)

Fermentable fibers/prebiotics (resistant starch, inulin)

High-fiber diet

Risk & Side Effects

Medium: Gastrointestinal discomfort

Low: Unpleasant odor and taste; headache, fatigue, and lightheadedness; transient metabolic and hematologic changes

Speculative: Theoretical pro-inflammatory or immune effects; effects in pregnancy and lactation

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation, the main proposed systemic benefit
Fasting glucose	70–90 mg/dL	Screens for the metabolic effects seen in animal models
Fasting insulin	2–6 µIU/mL	More sensitive than glucose for insulin sensitivity, a key preclinical benefit
HbA1c	< 5.4%	Longer-term glucose control marker
ALT	< 25 U/L (men), < 20 U/L (women)	Monitors liver, the organ with the most preclinical benefit data
Complete blood count (hemoglobin/hematocrit)	Hemoglobin 13.5–17 g/dL (men), 12–15.5 g/dL (women)	Detects the anemia signal seen at high oncology doses
eGFR / creatinine	eGFR > 90 mL/min/1.73m²; creatinine mid-normal	Detects the azotemia signal seen at high oncology doses

Cadence: Record baseline values before starting; recheck at roughly 3 months after a stable dose, then every 6–12 months, with more frequent review at higher doses or if symptoms arise.

Qualitative Assessment

Digestive comfort and regularity (stool form and frequency, bloating, cramping)
Energy levels and post-meal sensation
Cognitive clarity and mood (especially relevant to the gut–brain rationale)
Overall gut "resilience" during dietary changes, travel, or stress

Tributyrin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment